Completion axillary lymph node dissection for the identification of pN2–3 status as an indication fo...
Completion axillary lymph node dissection for the identification of pN2–3 status as an indication for adjuvant CDK4/6 inhibitor treatment: a post-hoc analysis of the randomised, phase 3 SENOMAC trial
About this item
Full title
Author / Creator
de Boniface, Jana, Prof , Appelgren, Matilda, OCN , Szulkin, Robert, PhD , Alkner, Sara, MD PhD , Andersson, Yvette, MD PhD , Bergkvist, Leif, Prof , Frisell, Jan, Prof , Gentilini, Oreste Davide, MD , Kontos, Michalis, MD , Kühn, Thorsten, Prof , Lundstedt, Dan, MD PhD , Offersen, Birgitte Vrou, Prof , Olofsson Bagge, Roger, Prof , Reimer, Toralf, Prof , Sund, Malin, Prof , Christiansen, Peer, Prof , Rydén, Lisa, Prof , Filtenborg Tvedskov, Tove, Prof , SENOMAC Trialists’ Group , SENOMAC Trialists' Group , Faculty of Medicine , Medicinska fakulteten , Övriga starka forskningsmiljöer , Other Strong Research Environments , LUCC: Lund University Cancer Centre , Institutionen för kliniska vetenskaper, Lund , The Liquid Biopsy och Tumörprogression i Bröstcancer , Section I , Breast cancer treatment , Lunds universitet , Bröstcancerkirurgi , Sektion I , Department of Clinical Sciences, Lund , Surgery (Lund) , Breast Cancer Surgery , Profilområden och andra starka forskningsmiljöer , Lund University , Sektion V , Bröstcancerbehandling , The Liquid Biopsy and Tumor Progression in Breast Cancer , Profile areas and other strong research environments , Section V , Kirurgi, Lund and LUCC: Lunds universitets cancercentrum
Publisher
England: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
SummaryBackgroundIn luminal breast cancer, adjuvant CDK4/6 inhibitors (eg, abemaciclib) improve invasive disease-free survival. In patients with T1–2, grade 1–2 tumours, and one or two sentinel lymph node metastases, completion axillary lymph node dissection (cALND) is the only prognostic tool available that can reveal four or more nodal metastases...
Alternative Titles
Full title
Completion axillary lymph node dissection for the identification of pN2–3 status as an indication for adjuvant CDK4/6 inhibitor treatment: a post-hoc analysis of the randomised, phase 3 SENOMAC trial
Authors, Artists and Contributors
Author / Creator
Appelgren, Matilda, OCN
Szulkin, Robert, PhD
Alkner, Sara, MD PhD
Andersson, Yvette, MD PhD
Bergkvist, Leif, Prof
Frisell, Jan, Prof
Gentilini, Oreste Davide, MD
Kontos, Michalis, MD
Kühn, Thorsten, Prof
Lundstedt, Dan, MD PhD
Offersen, Birgitte Vrou, Prof
Olofsson Bagge, Roger, Prof
Reimer, Toralf, Prof
Sund, Malin, Prof
Christiansen, Peer, Prof
Rydén, Lisa, Prof
Filtenborg Tvedskov, Tove, Prof
SENOMAC Trialists’ Group
SENOMAC Trialists' Group
Faculty of Medicine
Medicinska fakulteten
Övriga starka forskningsmiljöer
Other Strong Research Environments
LUCC: Lund University Cancer Centre
Institutionen för kliniska vetenskaper, Lund
The Liquid Biopsy och Tumörprogression i Bröstcancer
Section I
Breast cancer treatment
Lunds universitet
Bröstcancerkirurgi
Sektion I
Department of Clinical Sciences, Lund
Surgery (Lund)
Breast Cancer Surgery
Profilområden och andra starka forskningsmiljöer
Lund University
Sektion V
Bröstcancerbehandling
The Liquid Biopsy and Tumor Progression in Breast Cancer
Profile areas and other strong research environments
Section V
Kirurgi, Lund
LUCC: Lunds universitets cancercentrum
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_swepub_primary_oai_swepub_ki_se_879415
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_swepub_ki_se_879415
Other Identifiers
ISSN
1470-2045,1474-5488
E-ISSN
1474-5488
DOI
10.1016/S1470-2045(24)00350-4
How to access this item
ERROR: Invalid URL specified.
